Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer|Breast Tumors|Cancer of the Breast|Neoplasms, Breast|Tumors, Breast
Interventions: DRUG: Eribulin|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pegfilgrastim
Sponsor: Emory University
Collaborators: Eisai Inc.